Valuation: CanSino Biologics Inc.

Market Cap 12.03B 14.15B 1.8B 1.61B 1.49B 1.35B 2.53B 172B 2.57B 17.95B 7.1B 89.74B 6.77B 6.62B 284B P/E 2026 *
56.6x
P/E 2027 * 19x
Enterprise Value 12.06B 14.18B 1.81B 1.62B 1.49B 1.35B 2.53B 172B 2.57B 17.99B 7.12B 89.92B 6.78B 6.64B 285B EV / Sales 2026 *
8.37x
EV / Sales 2027 * 6.87x
Free-Float
39.57%
Yield 2026 *
-
Yield 2027 * -
1 day+2.33%
1 week-4.35%
Current month-20.63%
1 month-4.54%
3 months+24.04%
6 months-11.69%
Current year-16.95%
1 week 26.44
Extreme 26.44
31.2
1 month 26.44
Extreme 26.44
40.84
Current year 19.22
Extreme 19.22
41.64
1 year 19.22
Extreme 19.22
47.8
3 years 14.8
Extreme 14.8
56.55
5 years 14.8
Extreme 14.8
222.8
10 years 14.8
Extreme 14.8
450
Manager TitleAgeSince
Corporate Officer/Principal 66 20/02/2024
Chief Tech/Sci/R&D Officer 53 12/01/2009
Chief Executive Officer 62 12/01/2009
Director TitleAgeSince
Chairman 62 12/01/2009
Director/Board Member 63 21/06/2018
Director/Board Member 44 10/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/25 Sell

Director

4,600 0.0069%
26/09/24 Other

Chief Executive Officer

20,000 0.0151%
09/09/24 Other

Founder

30,000 0.0226%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%-4.35%-31.73%+28.04% 1.77B
+0.45%+1.76%+54.96%+118.11% 1,135B
+0.94%+4.20%+39.86%+75.69% 635B
+0.39%+0.46%+25.77%+97.40% 505B
+1.43%+4.56%+46.20%+66.91% 378B
-3.21%-3.66%+60.72%+35.68% 358B
-0.41%+2.23%+22.48%+48.54% 295B
+0.23%+3.28%+2.57%+21.89% 266B
+1.22%+2.81%+52.40%+63.37% 237B
+1.70%+1.60%+31.21%+102.44% 193B
Average +0.45%+0.79%+30.44%+65.81% 400.54B
Weighted average by Cap. +0.24%+1.63%+41.37%+81.01%

Financials

2026 *2027 *
Net sales 1.44B 1.69B 216M 193M 179M 162M 303M 20.54B 308M 2.15B 850M 10.74B 810M 793M 34.01B 1.81B 2.13B 272M 243M 225M 203M 381M 25.84B 387M 2.7B 1.07B 13.52B 1.02B 998M 42.79B
Net income 107M 126M 16.04M 14.34M 13.27M 12.01M 22.48M 1.53B 22.85M 160M 63.15M 798M 60.19M 58.9M 2.53B 322M 379M 48.29M 43.18M 39.95M 36.17M 67.7M 4.59B 68.81M 481M 190M 2.4B 181M 177M 7.61B
Net Debt 24.02M 28.24M 3.6M 3.22M 2.98M 2.7M 5.05M 343M 5.13M 35.84M 14.18M 179M 13.51M 13.22M 567M 415M 488M 62.21M 55.63M 51.47M 46.6M 87.22M 5.92B 88.65M 619M 245M 3.1B 233M 229M 9.8B
Projected Income Statement - Annual - CanSino Biologics Inc.
Logo CanSino Biologics Inc.
CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The Company is also engaged in the research and development of pharmaceutical production processes. The Company conducts its business in the domestic and overseas markets.
Employees
1,175
Date Price Change Volume
26/10/26 HK$29.00 +2.33% 3,209,400
23/10/26 HK$28.34 -2.07% 3,675,997
22/10/26 HK$28.94 -3.85% 2,467,146
21/10/26 HK$30.10 +2.73% 3,976,153
20/10/26 HK$29.30 -3.36% 3,548,457
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - CanSino Biologics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
24.66CNY
Average target price
40.47CNY
Spread / Average Target
+64.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CanSino Biologics Inc.
  1. Stock Market
  2. Stocks
  3. 6185 Stock